An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Quantum-Si to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Quantum-Si Incorporated (Nasdaq: QSI) announced participation in the Morgan Stanley 20th Annual Global Healthcare Conference from September 12-14, 2022, in New York, NY. Patrick Schneider, President and COO, will engage in a fireside chat on September 14, 2022, at 10:35 am ET. The discussion will focus on the company's advancements toward commercialization of the Platinum™ instrument, a pioneering platform for single-molecule protein sequencing. A live and archived webcast will be available in the Investors section of Quantum-Si's website.
Positive
None.
Negative
None.
GUILFORD, Conn.--(BUSINESS WIRE)--
Aug. 26, 2022 -- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a life sciences company commercializing the first-next generation single-molecule protein sequencing platform, today announced that it will be participating in the Morgan Stanley 20th Annual Global Healthcare Conference taking place at the Sheraton New York, NY, on September 12-14, 2022.
Patrick Schneider, Quantum-Si’s President and Chief Operating Officer, will participate in fireside chat on Wednesday, September 14, 2022 at 10:35 am ET. The discussions will cover recent company developments, including progress toward commercialization of Quantum-Si’s groundbreaking Platinum™ instrument, which will be the first system to enable next-generation, single-molecule protein sequencing.
A live and archived webcast of the events will be available in the Investors section of the Quantum-Si website under Events & Presentations.
About Quantum-Si Incorporated Quantum-Si is focused on revolutionizing the growing field of proteomics. The Company's suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable single-molecule next-generation protein sequencing and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing. Learn more at www.quantum-si.com.
